MXPA03005032A - Composiciones farmaceuticas para potenciar inmunogenicidad de antigenos poco inmunogenicos. - Google Patents

Composiciones farmaceuticas para potenciar inmunogenicidad de antigenos poco inmunogenicos.

Info

Publication number
MXPA03005032A
MXPA03005032A MXPA03005032A MXPA03005032A MXPA03005032A MX PA03005032 A MXPA03005032 A MX PA03005032A MX PA03005032 A MXPA03005032 A MX PA03005032A MX PA03005032 A MXPA03005032 A MX PA03005032A MX PA03005032 A MXPA03005032 A MX PA03005032A
Authority
MX
Mexico
Prior art keywords
immunogenicity
pharmaceutical compositions
compositions disclosed
poorly immunogenic
immunogenic antigens
Prior art date
Application number
MXPA03005032A
Other languages
English (en)
Inventor
Rodriguez Rolando Perez
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CU20000285A external-priority patent/CU23000A1/es
Priority claimed from CU20010167A external-priority patent/CU23009A1/es
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of MXPA03005032A publication Critical patent/MXPA03005032A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se relaciona con la Inmunologia y mas especificamente con composiciones inmunogenicas que contienen peptidos, polipeptidos, proteinas, sus correspondientes secuencias de ADN, celulas o sus lisados y proteoliposomas de muy pequena talla (VSSP), formados estos ultimos al unir el complejo de proteinas de la membrana externa (CPME) de Neisseria meningitidis con gangliosidos, mediante enlaces hidrofobos. En particular esta invencion muestra como preparar composiciones inmunoestimuladoras capaces de generar respuestas inmunes antigeno-especificas inclusive en huespedes inmunocomprometidos, como son los que padecen de cancer e infecciones de origen viral o bacterianas cronicas. En estos pacientes, la administracion de las composiciones vacunales descritas permite restaurar la funcionalidad de sectores de su sistema inmunitario. Las composiciones vacunales de esta invencion pueden ser utilizadas para proteger de o tratar enfermedades infecciosas, malignas o autoinmunes.
MXPA03005032A 2000-12-06 2001-12-06 Composiciones farmaceuticas para potenciar inmunogenicidad de antigenos poco inmunogenicos. MXPA03005032A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU20000285A CU23000A1 (es) 2000-12-06 2000-12-06 Composiciones vacunales para la inmunoterapia activa específica del cáncer
CU20010167A CU23009A1 (es) 2001-07-12 2001-07-12 Preparaciones para potenciar la inmunogenicidad depreparaciones para potenciar la inmunogenicidad de antígenos poco inmunogénicos antígenos poco inmunogénicos
PCT/CU2001/000010 WO2002045746A2 (es) 2000-12-06 2001-12-06 Composiciones farmaceuticas para potenciar la inmunogenicidad de antigenos poco inmunogenicos

Publications (1)

Publication Number Publication Date
MXPA03005032A true MXPA03005032A (es) 2004-09-10

Family

ID=38812545

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03005032A MXPA03005032A (es) 2000-12-06 2001-12-06 Composiciones farmaceuticas para potenciar inmunogenicidad de antigenos poco inmunogenicos.

Country Status (20)

Country Link
US (1) US7776342B2 (es)
EP (1) EP1356822B1 (es)
JP (1) JP4210519B2 (es)
KR (1) KR100850473B1 (es)
CN (1) CN1291755C (es)
AR (1) AR031638A1 (es)
AT (1) ATE485833T1 (es)
AU (2) AU2002221519B2 (es)
BR (1) BRPI0116013B8 (es)
CA (1) CA2431188C (es)
DE (1) DE60143363D1 (es)
DK (1) DK1356822T3 (es)
EA (1) EA005138B1 (es)
HK (1) HK1063726A1 (es)
MX (1) MXPA03005032A (es)
NZ (1) NZ526282A (es)
PE (1) PE20020572A1 (es)
UY (1) UY27059A1 (es)
WO (1) WO2002045746A2 (es)
ZA (1) ZA200304411B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1358910A1 (de) * 2002-05-02 2003-11-05 B.R.A.H.M.S Aktiengesellschaft Verfahren und Mittel zur Prävention, Hemmung und Therapie von Krebserkrankungen
EP1367395A1 (de) * 2002-05-02 2003-12-03 B.R.A.H.M.S Aktiengesellschaft Diagnose von Neoplasmen mit Hilfe von anti-Gangliosid-Antikörpern
CU23257A1 (es) * 2003-02-27 2008-01-24 Centro Inmunologia Molecular COMPOSICIONES VACUNALES A BASE DE GANGLIOSIDOS PARA LA ADMINISTRACION SUBCUTáNEA
AR045815A1 (es) * 2003-10-09 2005-11-16 Ct Ingenieria Genetica Biotech Composiciones farmaceuticas que contienen antigenos del virus de papiloma humano
WO2005111079A2 (en) * 2004-05-14 2005-11-24 The United States Of America As Represented By The Secretary Department Of Health And Human Services Hiv vaccine immunogens and immunization strategies to elicit broadly-neutralizing anti-hiv-1 antibodies against the membrane proximal domain of hiv gp41
WO2010003219A1 (en) * 2008-06-17 2010-01-14 Universite Laval Compositions comprising salmonella porins and uses thereof as adjuvants and vaccines
MX345854B (es) * 2010-12-22 2017-02-17 Bayer Ip Gmbh Respuesta inmune potenciada en la especie bovina.
KR101323845B1 (ko) * 2011-01-21 2013-10-31 광주과학기술원 외막소포체를 유효성분으로 포함하는 항암용 약제학적 조성물
CU24070B1 (es) * 2011-12-27 2015-01-29 Ct De Inmunología Molecular Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)
KR102427429B1 (ko) * 2013-03-15 2022-08-01 인3바이오 리미티드 자기조립형 합성 단백질
CU24299B1 (es) * 2013-08-02 2017-12-08 Centro De Inmunología Molecular Composiciones vacunales bivalentes basadas en los receptores de tipo 1 y 2 del factor de crecimiento epidérmico
US10105306B2 (en) * 2013-09-17 2018-10-23 Bestop Group Holdings Limited Method of preparing a growth factor concentrate
HK1194912A2 (en) * 2013-09-17 2014-10-24 Bestop Group Holdings Ltd Growth factor concentrate and the use thereof
CA2941416C (en) * 2014-03-11 2022-10-18 Universite D'aix-Marseille A chimeric peptide that interacts with cell membrane gangliosides
AU2018234783A1 (en) 2017-03-15 2019-10-10 Centro De Inmunologia Molecular Method for the treatment of patients with carcinomas
US12019073B2 (en) * 2017-03-15 2024-06-25 Centro De Inmunologia Molecular Method for the treatment of patients with carcinomas
US11890335B2 (en) * 2017-09-27 2024-02-06 L2 Diagnostics, Llc ErbB peptide pharmaceutical and vaccine compositions and therapeutic uses thereof for cancer
CU24534B1 (es) * 2017-11-06 2021-07-02 Ct Inmunologia Molecular Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3
CU20170173A7 (es) * 2017-12-27 2019-11-04 Ct Inmunologia Molecular Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras
CN109865137A (zh) * 2019-01-23 2019-06-11 天德悦（北京）生物科技有限责任公司 经碘代乙酰基活化的琼脂糖微球在提高多肽或蛋白类免疫原免疫原性中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857637A (en) * 1986-05-07 1989-08-15 Genentech, Inc. Methods and compositions for immunologically modulating growth hormone receptor activity
IT1206250B (it) * 1987-02-18 1989-04-14 Ist Farmacoterapico It Spa Stiche umane e relativi prodotti metodo per l'estrazione di antigeni di membrana aventi proprieta' immunogene a partire da cellule neopla-
US5726292A (en) * 1987-06-23 1998-03-10 Lowell; George H. Immuno-potentiating systems for preparation of immunogenic materials
TNSN93075A1 (fr) 1992-07-08 1994-03-17 Schering Corp Utilisation de gm-csf comme adjuvant pour vaccin
DE69428763T2 (de) * 1993-12-09 2002-08-01 Centro De Inmunologia Molecular, Ciudad De La Habana Monoklonale Antikörper gegen Ganglioside und deren Verwendung in der spezifischen, aktiven Immuntherapie gegen bösartige Tumoren
US6149921A (en) * 1993-12-29 2000-11-21 Centro De Inmunologia Molecular Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
CU22420A1 (es) 1993-12-29 1996-01-31 Centro Inmunologia Molecular Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
DE69931749T2 (de) * 1998-01-16 2007-05-31 Biomira Usa Inc. Von membran-proteoliposomen patient-spezifischen bösartigen weissen blutzellen impstoff

Also Published As

Publication number Publication date
PE20020572A1 (es) 2002-07-31
JP4210519B2 (ja) 2009-01-21
JP2004523494A (ja) 2004-08-05
US7776342B2 (en) 2010-08-17
HK1063726A1 (en) 2005-01-14
EA005138B1 (ru) 2004-12-30
EP1356822A2 (en) 2003-10-29
WO2002045746A3 (es) 2002-12-27
US20020136735A1 (en) 2002-09-26
AR031638A1 (es) 2003-09-24
ZA200304411B (en) 2004-07-29
EP1356822B1 (en) 2010-10-27
CN1484532A (zh) 2004-03-24
UY27059A1 (es) 2002-04-26
ATE485833T1 (de) 2010-11-15
CA2431188C (en) 2010-09-07
WO2002045746A2 (es) 2002-06-13
NZ526282A (en) 2005-01-28
BRPI0116013B8 (pt) 2021-05-25
CA2431188A1 (en) 2002-06-13
KR20030061838A (ko) 2003-07-22
DK1356822T3 (da) 2011-02-07
DE60143363D1 (de) 2010-12-09
BR0116013A (pt) 2004-01-06
BRPI0116013B1 (pt) 2018-07-24
CN1291755C (zh) 2006-12-27
EA200300640A1 (ru) 2003-12-25
KR100850473B1 (ko) 2008-08-07
AU2002221519B2 (en) 2006-11-23
AU2151902A (en) 2002-06-18

Similar Documents

Publication Publication Date Title
MXPA03005032A (es) Composiciones farmaceuticas para potenciar inmunogenicidad de antigenos poco inmunogenicos.
MXPA05009289A (es) Conjugados de particulas tipo virus del analogo del peptido melan-a.
IL134341A0 (en) Compositions for inducing an immune response containing an hpv protein antigen
WO2008040362A3 (en) Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies
WO2002061113A3 (en) Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation
CN108743937B (zh) 疫苗组合物和方法
GEP20022695B (en) Moraxella Catarrhalis Outer Membrane Protein-106 Polypeptide, Gene Sequence and Uses Thereof
GB2255093A (en) Hiv-1 core protein fragments
McDonald et al. Synthesis of a self-adjuvanting MUC1 vaccine via diselenide-selenoester ligation-deselenization
HUP9901039A2 (hu) Neisseria meningitidis B-csoportba tartozó külső-membrán-fehérjéjének (MB3) expressziója élesztőben, továbbá vakcinák
Ashhurst et al. Mucosal vaccination with a self-adjuvanted lipopeptide is immunogenic and protective against Mycobacterium tuberculosis
Gupta et al. Vaccine adjuvants: the current necessity of life
Layton et al. Induction of single and dual cytotoxic T‐lymphocyte responses to viral proteins in mice using recombinant hybrid Ty–virus‐like particles
JP2004523494A5 (es)
Olivera et al. Protective cellular immune response against hepatitis C virus elicited by chimeric protein formulations in BALB/c mice
Zahn et al. A new approach for therapeutic vaccination against chronic HBV infections
CN111295200A (zh) 作为疫苗中的佐剂的包含合成的神经节苷脂gm3变体的纳米颗粒
CN105031646A (zh) 抗肿瘤疫苗佐剂、其制备方法和编码核酸以及抗肿瘤疫苗组合物
MY129626A (en) Preparations that potentiate immunogenicity in low immunogenic antigens
RU2006123414A (ru) Белок nmb0928 и его применение в фармацевтических композициях
CA2552271A1 (en) Proteoliposomes and its derivatives as adjuvants inducers of citotoxic response and the resultant formulations
CU23009A1 (es) Preparaciones para potenciar la inmunogenicidad depreparaciones para potenciar la inmunogenicidad de antígenos poco inmunogénicos antígenos poco inmunogénicos
WO2000047229A3 (en) Polynucleotide encoding multimers of antigenic peptides in order to enhance presentation of the antigenic peptide by mhc molecules
WO2002048175A3 (en) Mhc class i associated peptides for prevention and treatment of tuberculosis
Jenkins et al. Enhanced delivery systems for enteric antigen uptake in teleosts

Legal Events

Date Code Title Description
FG Grant or registration